



## MEDICAL POLICY STATEMENT GEORGIA MEDICAID

<b>Original Issue Date</b>	<b>Next Annual Review</b>	<b>Effective Date</b>
02/22/2018	07/15/2019	07/15/2018
<b>Policy Name</b>		<b>Policy Number</b>
Facet Medial Branch Nerve Blocks		MM-0214
<b>Policy Type</b>		
<b>MEDICAL</b>	Administrative	Pharmacy
		Reimbursement

Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) are derived from literature based on and supported by clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures.

Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced in the Medical Policy Statement. If there is a conflict between the Medical Policy Statement and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination

### Contents of Policy

<u>MEDICAL POLICY STATEMENT</u> .....	1
<u>TABLE OF CONTENTS</u> .....	1
<u>A. SUBJECT</u> .....	2
<u>B. BACKGROUND</u> .....	2
<u>C. DEFINITIONS</u> .....	2
<u>D. POLICY</u> .....	3
<u>E. CONDITIONS OF COVERAGE</u> .....	5
<u>F. RELATED POLICIES/RULES</u> .....	5
<u>G. REVIEW/REVISION HISTORY</u> .....	5
<u>H. REFERENCES</u> .....	5



## A. SUBJECT

### Facet Medial Branch Nerve Blocks

## B. BACKGROUND

Interventional procedures for management of acute and chronic pain are part of a comprehensive pain management care plan that incorporates conservative treatment in a multimodality approach. Multidisciplinary treatments include promoting patient self-management and aim to reduce the impact of pain on a patient's daily life, even if the pain cannot be relieved completely. Interventional procedures for the management of pain unresponsive to conservative treatment should be provided only by physicians qualified to deliver these health services.

Facet medial branch nerve blocks is a method to diagnose and treat posterior biomechanical pain of the back that does not have a strong radicular component. Evidence supports the use of a Facet Medial Branch Nerve Block as a diagnostic tool to identify the cause of pain and as an option for providing short term pain relief with the use of certain medications. A presumptive diagnosis of facet joint pain is made clinically. Evaluations include response to facet loading on physical examination, and plain radiography or axial imaging indicating facet hypertrophy localized to the painful region. This may be confirmed by relief of pain through injection of local anesthetic to the medial branches of the posterior rami of the dorsal spinal nerves supplying the proposed facet joint(s). Pain is predominantly axial and, with the possible exception of facet joint cysts, not associated with radiculopathy or neurogenic claudication. There must be a lack of non-facet pathology that could explain the source of the patient's pain, such as fracture, tumor, infection, or significant deformity.

In the diagnostic phase, a patient receives injection of short-acting local anesthetic agent to identify the pain generator. For those patients with recurrent pain and pain that persists to a moderate-severe degree after positive diagnostic facet injection, interventional options may include a facet neurotomy which ablates the nerve, or facet medial branch nerve block injection(s), after the diagnostic phase is completed.

## C. DEFINITIONS

- A **zygapophyseal (aka facet) joint “level”** refers to the zygapophyseal joint or the two medial branch (MB) nerves that innervate that zygapophyseal joint.
- A **“session”** is defined as all injections/blocks/RF procedures performed on one day and includes medial branch blocks (MBB), intraarticular injections (IA), facet cyst ruptures, and radiofrequency (RF) ablations.
- **Conservative therapy** is a multimodality plan of care. Start and end dates in the medical record substantiate duration of treatment. Multimodality care plans include **BOTH** of the following:
  - **Active conservative therapies** such as physical therapy, occupational therapy, a physician supervised home exercise program (HEP), or chiropractic care
    - **Home Exercise Program (HEP):** includes two components that are both required to meet CareSource policy for completion of conservative therapy:
      - Information provided for an exercise prescription and/or plan documented in the medical record AND follow up documented in the medical record with member with information provided regarding completion of HEP (after suitable six (6) week period), or inability to complete HEP due to a stated physical reason- i.e. increased pain, inability to physically perform exercises. (Patient inconvenience or noncompliance without explanation does not constitute “inability to complete”)
  - **Passive conservative therapies** such as rest, ice, heat, medical devices, acupuncture, TENS unit, prescription medications.
    - If a TENS unit is part of the care plan, the frequency of use, and duration of use with dates must be documented in the medical record. General statements in the medical



record such as “Patient has a TENS unit” is insufficient documentation of use, and will not suffice to meet this policy criterion.

- A **TENS unit is a Transcutaneous Electrical Nerve Stimulator** is a durable medical equipment device dispensed by prescription. The use, frequency, duration, and start dates must be documented in the medical record to be considered part of conservative therapy during the period of prior authorization request.
- A “**successful**” **DIAGNOSTIC facet medial branch nerve block injection** in this policy is defined as an injection that achieves greater than 50% reduction in pain within the duration of effectiveness for the anesthetic used.
- A “**successful**” **THERAPEUTIC facet medial branch nerve block injection** in this policy is defined as an injection that achieves greater than 50% reduction in pain for at least 3 months.

## D. POLICY

### Criteria

- I. A prior authorization is required for each facet medial branch nerve block injection for pain management.
  - A. Facet Medial Branch Nerve Block Injections are indicated when **ALL** of the following criteria are met:
    1. Spine pain *is predominantly axial and non-radiating* and located in the cervical, thoracic, or lumbar spine. If pain is pseudo-radicular, the contemporaneous medical record must state this finding:
      - 1.1 ACTIVE conservative therapy as part of a multimodality comprehensive approach is addressed in the patient’s care plan with documentation in the medical record that includes at least **ONE of the following**:
        - a. The patient has received ACTIVE conservative therapy lasting for six (6) weeks or more within the past six (6) months with start and end dates in the medical record substantiating the duration of treatment including **ONE of the following**:
          - (1) Physical therapy
          - (2) Occupational therapy
          - (3) A physician supervised home exercise program (HEP) as defined in CareSource policy
          - (4) Chiropractic care
        - b. Or, the medical record documents at least **ONE of the following** exceptions to the 6 weeks ACTIVE conservative therapy requirement in the past 6 months:
          - (1) At least moderate pain with significant functional loss at work or home
          - (2) Severe pain unresponsive to outpatient medical management
          - (3) Inability to tolerate non-surgical, non-injection care due to co-existing medical condition(s)
          - (4) Prior successful injections for same specific condition with relief of at least 3 months’ duration (start and end dates are documented in the medical record).
      - 1.2 PASSIVE conservative therapy as part of a multimodality comprehensive approach is addressed in the patient’s care plan with documentation in the medical record lasting for six (6) weeks or more within the past six (6) months with start and end dates in the medical record substantiating the duration of treatment that includes at least **ONE of the following**:
        - a. rest
        - b. ice
        - c. heat
        - d. medical devices
        - e. acupuncture
        - f. TENS unit use as defined in CareSource policy



- g. prescription pain medications
  - 2. Relevant imaging studies of the painful spinal region were completed within 36 months prior to the date of this request.
- II. CareSource will consider a Facet Medial Branch Nerve Block Injection medically necessary for evaluation of predominantly non-radiating pain that is unresponsive to a well-managed course of conservative therapy when the following criteria exist:
- A. A thorough history and physical exam documenting cause of the pain if known, duration of symptoms, severity, exacerbating factors, abnormal physical and diagnostic findings and prior conservative treatment measures. If pain is pseudoradicular, the contemporaneous medical record must so state this finding.
  - B. Documentation of associated medical and psychological disorders
  - C. Diagnostic studies including x-rays and MRIs where appropriate that have confirmed the diagnosis of facet arthropathy or degenerative disease of the spine.

The evidence for cervical spine facet medial branch nerve block injections is fair. Available literature for thoracic spine facet medial branch nerve block injections shows Level II scientific evidence (criteria as described by the Agency for Healthcare Research and Quality [AHRQ] and the US Preventative Services Task Force (USPSTF) for diagnostic accuracy in 3 studies with a total of less than 200 subjects. For additional injections, three reports exist with 76% to 90% achieving relief at 12 months, but without placebo controls. Evidence is Level I or II-1 for diagnostic lumbar facet medial branch nerve block injections and good for lumbar facet medial branch nerve block injections in 11 randomized trials.

Prior to interventions, imaging studies should rule out other causes of spinal pain (examples include herniated disc, spinal stenosis, fracture or tumor). These imaging studies are completed within the 36 months prior to the date of the request for interventions. The treating physician should also verify that the patient has no blood clotting defect, is not on blood thinner medication, and does not have any infection.

Facet medial branch nerve blocks may be performed at the targeted joint itself, one joint above and one joint below on the same side, or bilaterally per treatment session.

A maximum of five (5) facet injection sessions inclusive of medial branch blocks, intraarticular injections, and facet cyst rupture and facet medial branch neurotomies may be performed per rolling 12 months in the cervical/thoracic spine and five (5) in the lumbar spine.

Facet medial branch nerve block injections should be performed with imaging guidance. Neither conscious sedation nor Monitored Anesthesia Care (MAC) is routinely necessary for facet joint medial branch blocks and are not routinely reimbursable. Individual consideration may be given for payment in rare unique circumstances if the medical necessity of sedation is unequivocal and clearly documented.

Patients with indwelling implanted spinal cord stimulators or pain pumps should have a device interrogation report submitted with medical records for a prior authorization request for proposed interventional pain injections. If a device is not functioning properly, an escalation in pain may warrant evaluation and management of the implanted device.

#### **Inconclusive or Non-Supportive Evidence**

Facet medial branch nerve block injections are unproven for the treatment of chronic spinal pain and routine, periodic injections will not be authorized for management of chronic pain.

Intra-articular facet joint injection for neck and back pain has limited evidence and the efficacy is not established. Intra-articular facet joint injection is a third option for managing axial back pain, however, due to poor evidence for efficacy facet joint injections, these injections are



therefore not covered. Intra-articular facet joint injections also do not qualify as diagnostic information for a future proposed neurotomy.

**E. CONDITIONS OF COVERAGE**

**HCPCS**

**CPT**

**AUTHORIZATION PERIOD**

**F. RELATED POLICIES/RULES**

Pain Management: PY-0432

**G. REVIEW/REVISION HISTORY**

DATES		ACTION
<b>Date Issued</b>	02/22/2018	New Policy.
<b>Date Revised</b>		
<b>Date Effective</b>	07/15/2018	

**H. REFERENCES**

1. R. Chou, A. Qaseem, V. Snow, D. Casey, J. T. Cross, Jr., P. Shekelle, *et al.*, "Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society," *Ann Intern Med*, vol. 147, pp. 478-91, Oct 2 2007.
2. R. Chou, L. H. Huffman, S. American Pain, and P. American College of, "Nonpharmacologic therapies for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline," *Ann Intern Med*, vol. 147, pp. 492-504, Oct 2 2007.
3. R. Chou, L. H. Huffman, S. American Pain, and P. American College of, "Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline," *Ann Intern Med*, vol. 147, pp. 505-14, Oct 2 2007.
4. R. Chou, J. D. Loeser, D. K. Owens, R. W. Rosenquist, S. J. Atlas, J. Baisden, *et al.*, "Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society," *Spine*, vol. 34, pp. 1066-1077, 2009.
5. L. Manchikanti, S. Abdi, S. Atluri, R. M. Benyamin, M. V. Boswell, R. M. Buenaventura, *et al.*, "An update of comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain. Part II: guidance and recommendations," *Pain Physician*, vol. 16, pp. S49-283, Apr 2013.
6. L. Manchikanti, F. J. Falco, V. Singh, R. M. Benyamin, G. B. Racz, S. Helm, 2nd, *et al.*, "An update of comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain. Part I: introduction and general considerations," *Pain Physician*, vol. 16, pp. S1-48, Apr 2013.
7. V. Mooney and J. Robertson, "The facet syndrome," *Clinical Orthopaedics and related research*, vol. 115, pp. 149-157, 1976.
8. M. V. Boswell, L. Manchikanti, A. D. Kaye, S. Bakshi, C. G. Gharibo, S. Gupta, *et al.*, "A Best-Evidence Systematic Appraisal of the Diagnostic Accuracy and Utility of Facet (Zygapophysial) Joint Injections in Chronic Spinal Pain," *Pain Physician*, vol. 18, pp. E497-533, Jul-Aug 2015.
9. F. J. Falco, S. Datta, L. Manchikanti, N. Sehgal, S. Geffert, V. Singh, *et al.*, "An updated review of the diagnostic utility of cervical facet joint injections," *Pain Physician*, vol. 15, pp. E807-38, Nov-Dec 2012.



10. L. Manchikanti, M. V. Boswell, V. Singh, R. Derby, B. Fellows, F. J. Falco, *et al.*, "Comprehensive review of neurophysiologic basis and diagnostic interventions in managing chronic spinal pain," *Pain physician*, vol. 12, pp. E71-120, Jul-Aug 2009.
11. R. Marks, "Distribution of pain provoked from lumbar facet joints and related structures during diagnostic spinal infiltration," *Pain*, vol. 39, pp. 37-40, Oct 1989.
12. F. J. Falco, L. Manchikanti, S. Datta, B. W. Wargo, S. Geffert, D. A. Bryce, *et al.*, "Systematic review of the therapeutic effectiveness of cervical facet joint interventions: an update," *Pain Physician*, vol. 15, pp. E839-68, Nov-Dec 2012.
13. L. Manchikanti, V. Singh, F. J. Falco, K. A. Cash, and B. Fellows, "Comparative outcomes of a 2-year follow-up of cervical medial branch blocks in management of chronic neck pain: a randomized, double-blind controlled trial," *Pain Physician*, vol. 13, pp. 437-50, Sep-Oct 2010.
14. S. West, V. King, T. S. Carey, K. N. Lohr, N. McKoy, S. F. Sutton, *et al.*, "Systems to rate the strength of scientific evidence," *Evid Rep Technol Assess (Summ)*, pp. 1-11, Mar 2002.
15. R. P. Harris, M. Helfand, S. H. Woolf, K. N. Lohr, C. D. Mulrow, S. M. Teutsch, *et al.*, "Current methods of the US Preventive Services Task Force: a review of the process," *Am J Prev Med*, vol. 20, pp. 21-35, Apr 2001.
16. L. Manchikanti, V. Singh, F. J. Falco, K. A. Cash, and V. Pampati, "Effectiveness of thoracic medial branch blocks in managing chronic pain: a preliminary report of a randomized, double-blind controlled trial," *Pain Physician*, vol. 11, pp. 491-504, Jul-Aug 2008.
17. L. Manchikanti, V. Singh, F. J. Falco, K. A. Cash, V. Pampati, and B. Fellows, "Comparative effectiveness of a one-year follow-up of thoracic medial branch blocks in management of chronic thoracic pain: a randomized, double-blind active controlled trial," *Pain Physician*, vol. 13, pp. 535-48, Nov-Dec 2010.
18. L. Manchikanti, V. Singh, F. J. Falco, K. A. Cash, V. Pampati, and B. Fellows, "The role of thoracic medial branch blocks in managing chronic mid and upper back pain: a randomized, double-blind, active-control trial with a 2-year followup," *Anesthesiol Res Pract*, vol. 2012, p. 585806, 2012.
19. L. Manchikanti, S. Datta, S. Gupta, R. Munglani, D. A. Bryce, S. P. Ward, *et al.*, "A critical review of the American Pain Society clinical practice guidelines for interventional techniques: part 2. Therapeutic interventions," *Pain physician*, vol. 13, pp. E215-64, Jul-Aug 2010.
20. F. J. Falco, L. Manchikanti, S. Datta, N. Sehgal, S. Geffert, O. Onyewu, *et al.*, "An update of the systematic assessment of the diagnostic accuracy of lumbar facet joint nerve blocks," *Pain Physician*, vol. 15, pp. E869-907, Nov-Dec 2012.
21. L. Manchikanti, V. Singh, F. J. Falco, K. A. Cash, and V. Pampati, "Evaluation of lumbar facet joint nerve blocks in managing chronic low back pain: a randomized, double-blind, controlled trial with a 2-year follow-up," *Int J Med Sci*, vol. 7, pp. 124-35, 2010.
22. F. J. Falco, L. Manchikanti, S. Datta, N. Sehgal, S. Geffert, O. Onyewu, *et al.*, "An update of the effectiveness of therapeutic lumbar facet joint interventions," *Pain Physician*, vol. 15, pp. E909-53, Nov-Dec 2012.
23. I. Medtronic, *Medtronic Patient Programmer 37746. Pain therapy user manual for neurostimulation system models 37702, 37711, 37713, 37701, 37712, 37714, 37703, 37704, 37022*. Minneapolis, MN: Medtronic, 2012.
24. S. Datta, M. Lee, F. J. Falco, D. A. Bryce, and S. M. Hayek, "Systematic assessment of diagnostic accuracy and therapeutic utility of lumbar facet joint interventions," *Pain Physician*, vol. 12, pp. 437-60, Mar-Apr 2009.
25. S. P. Cohen, J. Y. Moon, C. M. Brummett, R. L. White, and T. M. Larkin, "Medial Branch Blocks or Intra-Articular Injections as a Prognostic Tool Before Lumbar Facet Radiofrequency Denervation: A Multicenter, Case-Control Study," *Reg Anesth Pain Med*, vol. 40, pp. 376-83, Jul-Aug 2015.

**The Medical Policy Statement detailed above has received due consideration as defined in the Medical Policy Statement Policy and is approved.**

*Independent medical review – 02/2018*